Stacey Petruzella

COMPREHENSIVE BÖOOD AND CANCER CENTER, Bakersfield, California, United States

Are you Stacey Petruzella?

Claim your profile

Publications (2)53.72 Total impact

  • Elizabeth B Claus · Stacey Petruzella · Darryl Carter · Stanislav Kasl
    [Show abstract] [Hide abstract]
    ABSTRACT: Limited data exist on long-term quality of life (QOL) for women diagnosed with breast carcinoma in situ (BCIS). Participants and The data are on 795 BCIS participants diagnosed among female residents of Connecticut from September 15, 1994 to March 14, 1998, and 702 controls frequency-matched to the case participants by 5-year age intervals and geography. These women were participants in a large, population-based case/control study and subsequent follow-up study. Telephone interviews at follow-up were used to collect data on QOL at 5 years from initial diagnosis or contact, using the Medical Outcomes Study, Center for Epidemiologic Studies-Depression, and CAGE (Cut down, Annoyed, Guilty, Eye-opener) alcohol consumption scales. QOL outcomes were compared by case/control status and by case treatment group: lumpectomy, lumpectomy with adjuvant radiation therapy, and mastectomy. At 5 years after diagnosis, women diagnosed with BCIS report levels of physical, emotional, and mental health functioning similar with those reported in a general healthy female population. Case participants and controls did not differ in reported levels of limitations due to physical health problems, bodily pain, social functioning, or overall physical functioning. Case participants who underwent lumpectomy with radiation reported lower levels of emotional functioning, general health perceptions, vitality, sexual interest, and overall mental health, as well as more depressive symptoms than did control subjects; although, the clinical significance of these statistical differences appears to be limited. At 5 years after treatment, women diagnosed with BCIS report good physical and emotional functioning relative to control populations.
    No preview · Article · Nov 2006 · Journal of Clinical Oncology
  • Source
    Elizabeth B Claus · Stacey Petruzella · Ellen Matloff · Darryl Carter
    [Show abstract] [Hide abstract]
    ABSTRACT: The distribution of BRCA1 and BRCA2 mutations in women diagnosed with noninvasive breast carcinoma is unknown. To estimate the BRCA1 and BRCA2 mutation prevalence in women with ductal carcinoma in situ (DCIS), unselected for age, family history, or ethnicity. The data were 369 DCIS cases diagnosed among female residents aged 20 to 79 years from the state of Connecticut between September 15, 1994, and March 14, 1998. These women were participants in a large population-based case-control study of breast carcinoma in situ. Telephone interviews were used to collect risk factor information and blood or buccal specimens were collected for BRCA1 and BRCA2 mutation testing. Prevalence of disease-associated mutations of BRCA1 and BRCA2 in women diagnosed with DCIS. Three (0.8%) and 9 (2.4%) of 369 DCIS cases had disease-associated mutations in BRCA1 or BRCA2, respectively. One woman had a mutation in both genes (BRCA1 W321X and BRCA2 3398del5). Carriers were significantly more likely than noncarriers to report a first-degree (mother, sister, or daughter) family history of breast cancer (odds ratio [OR], 3.7; 95% confidence interval [CI], 1.1-12.4), as well as a personal history of ovarian cancer. In addition, carriers were more likely than noncarriers to be diagnosed at an early age (<50 years) (OR, 3.4; 95% CI, 1.0-11.7), as well as to report at least 1 first-degree relative diagnosed with breast cancer before 50 years (OR, 10.6; 95% CI, 3.0-37.0). Ductal carcinoma in situ is a part of the breast/ovarian cancer syndromes defined by BRCA1 and BRCA2, with mutation rates similar to those found for invasive breast cancer. These findings suggest that patients with breast cancer with an appropriate personal or family history of breast and/or ovarian cancer should be screened and followed according to high-risk protocols, regardless of whether they are diagnosed with in situ or invasive breast cancer.
    Full-text · Article · Mar 2005 · JAMA The Journal of the American Medical Association

Publication Stats

73 Citations
53.72 Total Impact Points


  • 2006
      Bakersfield, California, United States
  • 2005
    • Yale-New Haven Hospital
      • Department of Pathology
      New Haven, Connecticut, United States